On April 2, Virpax Pharmaceuticals Inc Got Letter From Nasdaq Stating That Company Was Not In Compliance With Nasdaq Listing Rule
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals Inc received a letter from Nasdaq on April 2, indicating that the company is not in compliance with Nasdaq's listing rules, according to an SEC filing.
April 03, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Virpax Pharmaceuticals Inc was notified by Nasdaq of non-compliance with listing rules.
Receiving a non-compliance notice from Nasdaq is a significant regulatory issue that can affect investor confidence and potentially lead to delisting if not resolved. This news is likely to negatively impact VRPX's stock price in the short term as investors may perceive this as a sign of underlying problems within the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100